Cargando…

Impact of liver volume on polycystic liver disease-related symptoms and quality of life

BACKGROUND: Symptoms in polycystic liver disease (PLD) are thought to be caused by compression of organs and structures by the enlarged liver. AIM: The aim of this article is to assess the impact of liver volume on symptoms and quality of life (QoL) in PLD. METHODS: We included PLD patients from two...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neijenhuis, Myrte K, Kievit, Wietske, Verheesen, Stef MH, D’Agnolo, Hedwig M, Gevers, Tom JG, Drenth, Joost PH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802666/ https://www.ncbi.nlm.nih.gov/pubmed/29435317 http://dx.doi.org/10.1177/2050640617705577

Ejemplares similares

Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts
por: Neijenhuis, Myrte K., et al.
Publicado: (2018)

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease
por: Gevers, Tom JG, et al.
Publicado: (2012)

Estrogen‐Containing Oral Contraceptives Are Associated With Polycystic Liver Disease Severity in Premenopausal Patients
por: van Aerts, René M.M., et al.
Publicado: (2019)

The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression
por: Neijenhuis, Myrte K., et al.
Publicado: (2017)

Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life
por: Duijzer, Renée, et al.
Publicado: (2022)

Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
por: van Aerts, René M. M., et al.
Publicado: (2018)

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial
por: Chrispijn, Melissa, et al.
Publicado: (2011)

Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management
por: Cnossen, Wybrich R, et al.
Publicado: (2014)

Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly
por: Barten, Thijs R. M., et al.
Publicado: (2022)

Tamoxifen for the treatment of polycystic liver disease: A case report
por: Aapkes, Sophie E., et al.
Publicado: (2021)

Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial
por: Wijnands, Titus FM, et al.
Publicado: (2015)

Management of portal hypertension and ascites in polycystic liver disease
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
por: Betzel, Bark, et al.
Publicado: (2014)

Patient reported outcome measure thresholds: The next step in the management of polycystic liver disease
por: Duijzer, Renée, et al.
Publicado: (2023)

Heterozygosity of ALG9 in Association with Autosomal Dominant Polycystic Liver Disease
por: Boerrigter, Melissa M., et al.
Publicado: (2023)

Validation of a semi-automatic method to measure total liver volumes in polycystic liver disease on computed tomography — high speed and accuracy
por: Aapkes, Sophie E., et al.
Publicado: (2023)

Aspiration–sclerotherapy Results in Effective Control of Liver Volume in Patients with Liver Cysts
por: van Keimpema, Loes, et al.
Publicado: (2008)

Loss of Heterozygosity Is Present in SEC63 Germline Carriers with Polycystic Liver Disease
por: Janssen, Manoe J., et al.
Publicado: (2012)

Estrogens in polycystic liver disease: A target for future therapies?
por: Aapkes, Sophie E., et al.
Publicado: (2021)

Novel GANAB variants associated with polycystic liver disease
por: van de Laarschot, Liyanne F. M., et al.
Publicado: (2020)

Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis
por: Bernts, Lucas H. P., et al.
Publicado: (2018)

Novel α-1,3-Glucosyltransferase Variants and Their Broad Clinical Polycystic Liver Disease Spectrum
por: Boerrigter, Melissa M., et al.
Publicado: (2023)

Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts
por: Wijnands, Titus FM, et al.
Publicado: (2018)

Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE‐LIVER online survey
por: Wunsch, Ewa, et al.
Publicado: (2022)

Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis
por: Sierks, Dana, et al.
Publicado: (2022)

The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
por: Garofalo, Carlo, et al.
Publicado: (2021)

A TGFβ-ECM-Integrin signalling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease
por: Waddell, Scott H, et al.
Publicado: (2023)

Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models
por: Lee-Law, Pui Y., et al.
Publicado: (2020)

Autosomal Dominant Polycystic Kidney Disease in which the Polycystic Liver Volume Was Reduced by Rigorous Blood Pressure Control
por: Suwabe, Tatsuya, et al.
Publicado: (2021)

Cost-effectiveness of a new strategy to identify uncomplicated gallstone disease patients that will benefit from a cholecystectomy
por: Lamberts, Mark P., et al.
Publicado: (2016)

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study
por: Lantinga, Marten A., et al.
Publicado: (2016)

Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study
por: Kok, Karin F, et al.
Publicado: (2010)

Gastroparesis in patients with inactive Crohn's disease: a case series
por: Kristinsson, Jón O, et al.
Publicado: (2007)

The Longitudinal Study of Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease
por: Matsuura, Ryo, et al.
Publicado: (2016)

Liver transplantation in adult polycystic liver disease: the Ontario experience
por: Alsager, Mohammed, et al.
Publicado: (2021)

Inhibition of NAE‐dependent protein hyper‐NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease
por: Lee‐Law, Pui Y., et al.
Publicado: (2021)

Polycystic liver disease presenting as pruritus
por: Johnson, Deepak Kochummen, et al.
Publicado: (2014)

The management of polycystic liver disease by tolvaptan
por: Takenaka, Tsuneo, et al.
Publicado: (2020)

Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series
por: Bernts, Lucas H P, et al.
Publicado: (2020)

Liver Transplant for Unusually Large Polycystic Liver Disease: Challenges and Pitfalls
por: Serrano Rodriguez, Pablo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g2vobec606dmmft1elme606ft4